Autoimmune hepatitis (AIH) is an immunologically mediated inflammatory liver disorder of unknown etiology. It is characterized by increased immunoglobulin G (IgG) levels, the presence of autoantibodies, and various degrees of lymphocyte predominant inflammation and fibrosis histologically. Immunosuppressive therapy induces remission in approximately 80% of those affected. However, liver transplantation is indicated in patients with acute liver failure with encephalopathy at presentation. Liver supporting systems, including plasma exchange (PE) allow bridging patients to transplantation or spontaneous recovery in the setting of liver failure. The role of these systems has not been assessed in children with liver failure of autoimmune etiology.

Case. Herein, we report three cases of AIH with fulminant presentation, with marked symptom resolution with PE as an adjunct therapeutic option to immunosuppressive treatment.

Conclusion. In the setting of AIH, PE may have a special therapeutic role by removing autoantibodies and cytokines, therefore preventing further liver damage and decompensation, and allowing time for recovery.
or spontaneous recovery in the setting of liver failure. The role of these systems has not been assessed in children with liver failure of autoimmune etiology. Herein, we report three cases of AIH with fulminant presentation, with marked symptom resolution with PE adjunct to immunosuppressive treatment.

Case 1

A 6-year-old girl was admitted to the hospital with jaundice for the previous 6 days. There was no history of a particular illness or drug use. Family history was unremarkable. She was icteric, with slight hepatomegaly. Laboratory findings were aspartate aminotransferase (AST) 1314 IU/L, alanine aminotransferase (ALT) 837 IU/L, total bilirubin (TB) 28.17 mg/dl, direct bilirubin (DB) 24.31 mg/dl, INR 3.65 (unresponsive to vitamin K) and ammonia 57 mg/dl. Further investigations revealed IgG 4245.7 mg/dl (633-1280), ceruloplasmin 49.4 mg/dl, and a positive antinuclear antibody (ANA), titer ≥1/100. Viral serologies of Hepatitis A, B, C, E, Epstein-Barr Virus (EBV), and cytomegalovirus (CMV) were all negative. She rapidly progressed to grade 3 encephalopathy under prednisolone (2 mg/kg/day) and PE was started. After three daily sessions of PE, the patient was non-encephalopathic. After the second week of prednisolone treatment, azathioprine was added. Liver biopsy performed one month after hospitalization demonstrated minimal portal inflammation, giant cell formation, cholestasis, and grade 2 to 3 portal fibrosis. At the end of one month, the patient was tolerating the azathiopurine and the prednisolone dosage was tapered. She is in complete remission longer than 2 years with no recurrence (Table I).

Case 2

A 10-year-old boy presented with abdominal pain and jaundice. Laboratory tests revealed elevated transaminase levels. INR was 1.96 (unresponsive to vitamin K). Viral serologies were negative for Hepatitis A, B, C, EBV, and CMV. The anti-smooth muscle antibody (ASMA) test was positive (titer >1/160), and the serum IgG value was 4745 mg/dl (608-1572). A liver biopsy was not performed owing to coagulopathy. Prednisolone was started at a dosage of 2 mg/kg/day. On the 4th day of prednisolone administration, the patient developed grade 2 encephalopathy and the INR was 2.1. After three PE sessions, the patient showed improvement. Liver biopsy performed on the 20th day of prednisolone treatment demonstrated resolution of acute hepatitis, pericentral and periportal bridging fibrosis and necrosis along with portal mononuclear dominant mixed inflammatory cell infiltration. These biopsy findings under immunosuppressive treatment together with clinical and laboratory findings were supporting the diagnosis of AIH. He

<table>
<thead>
<tr>
<th>Table I. The course of ALT, bilirubin and INR values.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Days</td>
</tr>
<tr>
<td>------</td>
</tr>
<tr>
<td>Case 1</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Case 2</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Case 3</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

* Day 0; first day of plasmapheresis
ALT: alanine aminotransferase, INR: international normalized ratio.
was discharged on prednisolone treatment and all laboratory findings were normalized by the second month of treatment. He is now in complete remission without any recurrence longer than 3 years under low dose methylprednisolone and azathioprine (Table I).

**Case 3**

A 2-year-old girl was referred to the hospital with grade 2 encephalopathy. She had a three-month history of jaundice. Physical examination showed slight hepatomegaly and splenomegaly. Laboratory findings at presentation were as follows: AST 427 IU/L, ALT 412 IU/L, TB 15.43 mg/dl, DB 12.23 mg/dl, INR 3.51, and ammonia 187 mg/dl. Viral, toxic, and metabolic causes were excluded. Ig value was 1888 mg/dl (453-916). She tested positive for ANA (titer 1/160) and ASMA (titer 1/80). Prednisolone and PE treatments were commenced immediately. After three daily sessions of PE, she was non-encephalopathic. Despite the correction of the INR values, transaminases did not decrease and cyclosporine therapy (PO) was started. Liver biopsy demonstrated resolution of acute hepatitis along with slight portal mononuclear cell infiltration and pericentral and periportal fibrosis. Transaminase levels were declining and the INR value was completely normalized at the end of the first month following admission, while she was on prednisolone and cyclosporine. By the 3rd month of presentation, she was under the cyclosporine maintenance treatment. Unfortunately, she died of severe pneumonia and sepsis 6 months later while she was in complete remission (Table I).

**Discussion**

The mainstay of treatment in AIH is immunosuppressive therapy and should be instituted promptly to avoid progression to cirrhosis. The conventional treatment consists of prednisolone 2 mg/kg/day, which is gradually tapered in due course within 4-8 weeks, in parallel to decline in transaminase levels, to a maintenance dose of 2.5 to 5 mg/day. In the pediatric age, remission is defined as complete clinical recovery with transaminase levels within the normal range and is achieved in 60% to 90% of patients, except fulminant presentation with encephalopathy. The management of AIH with fulminant presentation is controversial. Steroid treatment in fulminant patients is considered to be of little benefit and increase septic complication in adults. On the other hand, recovery was reported in 4 out of 9 children referred to the transplant center while the remaining 5 required liver transplant despite steroids. Smolka at al. reported complete response in all 6 children presenting with AIH with encephalopathy. In a report from India, 2 out of 4 children with fulminant AIH responded to steroid treatment, the other 2 died due to progressive encephalopathy and infectious complications. Karakoyun et al. reported AIH with encephalopathy in 2 (4.3%) out of 44 patients who did not respond to steroid treatment and underwent living-related liver transplantation.

In the setting of acute liver failure, decompensation of liver function results in decreased biotransformation and excretion of toxic substances as well as synthetic functions. Most liver support systems are based on detoxification of water-soluble (ammonia, lactate, urea, GABA, amino acids, and cytokines) or albumin-bound (bile acids, bilirubin, free fatty acids, aromatic amino acids, indoles, phenols, mercaptans, and endogenous benzodiazepines) toxins. PE removes toxic substances and replaces essential substances by separating the patient's plasma from formed elements and replacing it with the same amount of fresh frozen plasma. High volume PE is considered as first line therapy in the setting of liver failure in adults, either as primary stand-alone treatment or in conjunction with other modes of treatment. Although PE is not recommended as standard of care for children with liver failure, it can be valuable as a temporizing measure because it rapidly removes large amounts of copper in patients with liver failure due to Wilson disease. Few studies of liver support systems...
have focused on pediatric patients and are mainly case series and retrospective studies. Most case series in children or adults with acute liver failure suggests that PE might improve coagulation profiles, vasopressor requirements, and encephalopathy grade scores.\textsuperscript{14-16} It can significantly decrease mortality in acute or acute-on-chronic liver failure by temporarily supporting liver functions until functional recovery or liver transplantation.\textsuperscript{17,18} On the other hand, Chien et al.\textsuperscript{19} reported in a case series of 23 pediatric patients that plasma exchange for more than six times probably offers little benefit with regard to patient survival in the absence of a timely liver transplant. In the present study, the first 2 cases developed encephalopathy under steroid treatment. The third case was already encephalopathic at admission. After three daily sessions of PE, all cases were clinically non-encephalopathic, coagulation profiles and liver biochemistry improved and did not progress to encephalopathy in due course. Sogo et al.\textsuperscript{20} recently reported 4 children that presented with fulminant hepatic failure all survived by PE therapy initiated together with steroid and cyclosporine treatment. The data is limited regarding the role of PE in children with fulminant AIH. Moreover, no such data are available in adults with fulminant AIH refractory to medical treatment but improved by plasmapheresis. Dumortier et al.\textsuperscript{21} are reported a case of a liver transplanted adult female patient who presented a severe de novo AIH, refractory to tacrolimus, mycophenolate mofetil and steroids, and who was treated with plasmapheresis. Only one case presenting with severe AIH-systemic lupus erythematosus overlap despite massive corticosteroid administration, and who improved with plasmapheresis therapy, has been reported.\textsuperscript{22}

Similar to the other liver supporting systems, PE allows bridging patients with acute liver failure to transplantation or spontaneous recovery. In the setting of AIH, however, it may have a special therapeutic role as an adjunct to immunosuppressive treatment by removing autoantibodies and cytokines, therefore preventing further liver damage and decompensation, and allowing time for recovery. However, the data is limited and future well-designed studies are needed exploring the role of PE in fulminant AIH.

REFERENCES


